Novartis’ VALIANT Effort: Diovan Gains Post-Myocardial Infarction Indication

FDA has approved Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line reduction of cardiovascular death in patients at high risk following myocardial infarction based on a non-inferiority analysis